This is a best-case Phase 3 readout for a pivotal asset. Expect significant upside at open. Monitor the NDA submission timeline and potential accelerated approval. The expanded access protocol signals FDA alignment. Long-term, watch for data in first-line PDAC and NSCLC trials which expand the addressable market.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $163.68entry
- T+1 · 6mo ago −7.56%α −7.70% · $151.31
- T+5 · 5mo ago −8.83%α −6.08% · $149.23
- T+20 · 5mo ago +14.42%α +15.72% · $187.28
- T+60 · 3mo ago +29.14%α +27.91% · $211.38
Price Chart
How similar events traded
Executive Summary
Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, showing a 60% reduction in risk of death and median OS of 13.2 months vs 6.6 months for chemotherapy. The company plans to file an NDA using a priority voucher, and the FDA has authorized an expanded access protocol. These results position daraxonrasib as a potential new standard of care in a high-unmet-need indication.
Key Facts
- Phase 3 RASolute 302 trial met all primary and key secondary endpoints in previously treated metastatic PDAC.
- Daraxonrasib reduced risk of death by 60% (HR 0.40) in both RAS G12 and ITT populations.
- Median OS: 13.2 months daraxonrasib vs 6.6 months chemotherapy in RAS G12 population.
- Median PFS: 7.3 months daraxonrasib vs 3.5 months chemotherapy in RAS G12 population.
- Objective response rate: 33.2% daraxonrasib vs 11.8% chemotherapy in RAS G12 population.
- Grade 3+ TRAEs: 43.6% daraxonrasib vs 57.5% chemotherapy; discontinuation rate 1.2% vs 11.2%.
- Company intends to submit NDA using FDA Commissioner's National Priority Voucher.
- FDA authorized expanded access treatment protocol (EAP) for daraxonrasib.
- Daraxonrasib has Breakthrough Therapy and Orphan Drug designations for this indication.
Financial Impact
Transformative for a $33.5B market cap company with no approved products. Daraxonrasib could address a ~$5B+ annual market in second-line metastatic PDAC alone, with additional Phase 3 trials in first-line PDAC and NSCLC. The data support rapid regulatory filing and potential blockbuster revenue.
Risk Factors
- Regulatory approval is not guaranteed; FDA may request additional data or have concerns about the single Grade 5 pneumonitis event.
- Competition from other RAS inhibitors in development (e.g., from Amgen, Mirati/BMS) could emerge.
- Commercial execution risk: launching a novel oral therapy requires new infrastructure for a company with no prior commercial products.
- Payer reimbursement dynamics for a high-cost targeted therapy in a palliative setting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303919 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers